Literature DB >> 32888499

Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.

Jing Zhang1, Liqiang Fu2, Bin Shen1, Yingtao Liu2, Wenqian Wang1, Xin Cai3, Linglong Kong2, Yilin Yan3, Ryan Meng4, Zhuming Zhang5, Ying-Nan P Chen1, Qian Liu2, Zhao-Kui Wan2, Tianyuan Zhou1, Xiaotao Wang3, Paul Gavine1, Amanda Del Rosario5, Kay Ahn5, Ulrike Philippar6, Ricardo Attar5, Jennifer Yang1, Yanping Xu2, James P Edwards5, Xuedong Dai7.   

Abstract

The interleukin-1 receptor-activated kinase 4 (IRAK4) belongs to the IRAK family of serine/threonine kinases and plays a central role in the innate immune response. However, the function of IRAK4 in tumor growth and progression remains elusive. Here we sought to determine the enzymatic and scaffolding functions of IRAK4 in activated B-cell-like diffuse large B cell lymphoma (ABC DLBCL). We chose a highly selective IRAK4 kinase inhibitor to probe the biological effects of kinase inhibition and developed a series of IRAK4 degraders to evaluate the effects of protein degradation in ABC DLBCL cells. Interestingly, the results demonstrated that neither IRAK4 kinase inhibition nor protein degradation led to cell death or growth inhibition, suggesting a redundant role for IRAK4 in ABC DLBCL cell survival. IRAK4 degraders characterized in this study provide useful tools for understanding IRAK4 protein scaffolding function, which was previously unachievable using pharmacological perturbation.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ABC DLBCL; IRAK4 PROTAC; MyD88; PROTAC; activated B-cell-like diffuse large B cell lymphoma; interleukin-1 receptor activated kinase 4 (IRAK4); myeloid differentiation primary response 88 signaling; proteolysis-targeting chimera; scaffolding activity of IRAK4; selective IRAK4 degrader

Mesh:

Substances:

Year:  2020        PMID: 32888499     DOI: 10.1016/j.chembiol.2020.08.010

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  8 in total

1.  Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins.

Authors:  Katarina Pance; Josef A Gramespacher; James R Byrnes; Fernando Salangsang; Juan-Antonio C Serrano; Adam D Cotton; Veronica Steri; James A Wells
Journal:  Nat Biotechnol       Date:  2022-09-22       Impact factor: 68.164

Review 2.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 3.  Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.

Authors:  Chao Wang; Yujing Zhang; Tingting Zhang; Lingyu Shi; Zhongmin Geng; Dongming Xing
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 4.  Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.

Authors:  Chao Wang; Yujing Zhang; Lingyu Shi; Shanbo Yang; Jing Chang; Yingjie Zhong; Qian Li; Dongming Xing
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 5.  IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies.

Authors:  Joshua Bennett; Daniel T Starczynowski
Journal:  Curr Opin Hematol       Date:  2022-01-01       Impact factor: 3.284

Review 6.  Proteolysis-targeting chimeras (PROTACs) in cancer therapy.

Authors:  Xinyi Li; Wenchen Pu; Qingquan Zheng; Min Ai; Song Chen; Yong Peng
Journal:  Mol Cancer       Date:  2022-04-11       Impact factor: 27.401

Review 7.  Targeted protein degradation: mechanisms, strategies and application.

Authors:  Lin Zhao; Jia Zhao; Kunhong Zhong; Aiping Tong; Da Jia
Journal:  Signal Transduct Target Ther       Date:  2022-04-04

Review 8.  PROTAC targeted protein degraders: the past is prologue.

Authors:  Miklós Békés; David R Langley; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2022-01-18       Impact factor: 112.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.